Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

2.

Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.

Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ.

J Clin Invest. 1994 Apr;93(4):1458-64.

3.

Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8474-8.

4.

Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system.

Ogata N, Otsuji T, Matsushima M, Kimoto T, Yamanaka R, Takahashi K, Wada M, Uyama M, Kaneda Y.

Curr Eye Res. 1999 Apr;18(4):261-9.

PMID:
10372985
5.

Prevention of restenosis by gene therapy.

Kaneda Y, Morishita R, Dzau VJ.

Ann N Y Acad Sci. 1997 Apr 15;811:299-308; discussion 308-10.

PMID:
9186606
6.

Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer.

Morishita R, Gibbons GH, Horiuchi M, Nakajima M, Ellison KE, Lee W, Kaneda Y, Ogihara T, Dzau VJ.

J Cardiovasc Pharmacol Ther. 1997 Jul;2(3):213-222.

PMID:
10684460
7.

In vivo reduction of the nuclear factor-kappaB activity using synthetic cis-element decoy oligonucleotides suppresses intimal hyperplasia in the injured carotid arteries in rabbits.

Takeuchi K, Itoh H, Yonemitsu Y, Matsumoto T, Kume M, Komori K, Maehara Y.

Surg Today. 2007;37(7):575-83. Epub 2007 Jun 26.

PMID:
17593477
8.
9.

In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method.

Aoki M, Morishita R, Higaki J, Moriguchi A, Kida I, Hayashi S, Matsushita H, Kaneda Y, Ogihara T.

Biochem Biophys Res Commun. 1997 Feb 24;231(3):540-5.

PMID:
9070840
10.

Gene transfer to vein graft wall by HVJ-liposome method: time course and localization of gene expression.

Bai HZ, Sawa Y, Zhang WD, Yamakawa T, Morishita R, Kaneda Y, Matsuda H.

Ann Thorac Surg. 1998 Sep;66(3):814-9; discussion 819-20.

PMID:
9768936
11.

In vivo delivery of phosphorothioate oligonucleotides into murine retina.

Hangai M, Tanihara H, Honda Y, Kaneda Y.

Arch Ophthalmol. 1998 Mar;116(3):342-8. Erratum in: Arch Ophthalmol 1998 Jul;116(7):976.

PMID:
9514488
12.
13.

Fusigenic liposome-mediated DNA transfer into cardiac myocytes.

Ellison KE, Bishopric NH, Webster KA, Morishita R, Gibbons GH, Kaneda Y, Sato B, Dzau VJ.

J Mol Cell Cardiol. 1996 Jul;28(7):1385-99.

PMID:
8841927
14.

Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery.

Abe J, Zhou W, Taguchi J, Takuwa N, Miki K, Okazaki H, Kurokawa K, Kumada M, Takuwa Y.

Biochem Biophys Res Commun. 1994 Jan 14;198(1):16-24.

PMID:
8292019
15.

Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (Hemagglutinating Virus of Japan)--liposome method.

Aoki M, Morishita R, Muraishi A, Moriguchi A, Sugimoto T, Maeda K, Dzau VJ, Kaneda Y, Higaki J, Ogihara T.

J Mol Cell Cardiol. 1997 Mar;29(3):949-59.

PMID:
9152856
16.
17.

Efficient oligonucleotide delivery using the HVJ-liposome method in the central nervous system.

Yamada K, Moriguchi A, Morishita R, Aoki M, Nakamura Y, Mikami H, Oshima T, Ninomiya M, Kaneda Y, Higaki J, Ogihara T.

Am J Physiol. 1996 Nov;271(5 Pt 2):R1212-20.

PMID:
8945956
18.
20.

Antisense strategies to inhibit restenosis.

Lee M, Simon AD, Stein CA, Rabbani LE.

Antisense Nucleic Acid Drug Dev. 1999 Oct;9(5):487-92. Review.

PMID:
10555157

Supplemental Content

Support Center